The effects of 14-day treatments with nerve growth factor (NGF), basic fibroblast growth factor (b-FGF), or the peptidergic drug Cerebrolysin on postlesion acquisition of a water maze task and on motor activity were evaluated. Rats were tested in the Morris water maze 14 days (early test) and 7 to 8 months (delayed test) after a bilateral lesion of the frontoparietal (sensorimotor) cortex. Only the rats treated with Cerebrolysin performed the water maze task at the level of the nonlesioned controls in the early test. No short-term effect of NGF (6.5 ng/14 days; 38 ng/ml) or b-FGF (17 ng/14 days; 100 ng/ml) treatment was found. The delayed test revealed that water maze performance was restored in rats treated with b-FGF in comparison with intact controls. The data showed that b-FGF can support or initiate processes in the CNS that lead to a delayed functional amelioration and/or compensation for a water maze performance deficit. NGF did not influence the acquisition impairment caused by a sensorimotor cortical lesion. Two-week administration of Cerebrolysin had a time-dependent influence: it attenuated the acquisition deficit and increased the motor activity of rats, both effects declined to the level of lesioned controls within 8 months.
INTRODUCTION
Spatial learning and memory impairments are the most prominent and consistent consequences of Alzheimer's disease (AD), aging-related dementia, and traumatic brain injury. Usually, animal models of AD focus on the impairment of the basal forebrain cholinergic system without taking into account that severely disturbed brain energy metabolism and degenerative changes, particularly in cortical areas, are other attributes of AD (Kalaria & Harik, 1989; Swerdlow, Marcus, Landman, Kooby, Frey, & Freedman, 1994) .
Spatial memory impairment is not always accompanied by neuronal loss in the basal cholinergic system, by changes in AChT activity, or by axonal injury of hippocampal pathways (Lyeth, Jenkins, Hamm, Dixon, Phillips, Clifton, Young, & Hayes, 1990; Pappas, de la Torre, Davidson, Keyes, & Fortin, 1996; Rapp & Gallagher, 1996; Rasmussen, Schliemann, Sorensen, Zimmer, & West, 1996) . Similarly, treatments attenuating memory dysfunction do not always
